Protalix Biotherapeutics

Company snapshot

Protalix (NYSE American, TASE: PLX) is a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins expressed through its proprietary plant cell-based expression system, ProCellEx. Protalix was the first company to gain U.S. Food and Drug Administration (FDA) approval of a protein produced through plant cell-based in suspension expression system.

• 21 active pipeline program(s) linked via ClinicalTrials.gov.
• 22 US patent(s) indexed to this assignee profile.
• 21 trial update(s) in the last 12 months.

Public regulatory, clinical, patent, and corporate records for Protalix Biotherapeutics. Not investment advice.

• Peer + 0 momentum

  Lakefront Biotherapeutics NV

  TA overlap score 49.8

• Peer + 0 momentum

  Eli Lilly and

  TA overlap score 32.4

Recent activity

Latest pipeline, patent, and corporate events for Protalix Biotherapeutics.

1. Jun 8, 2026 Clinical update

   PL2200 Aspirin Capsules — Phase 3

2. Jun 8, 2026 Clinical update

   Pegunigalsidase alfa — Phase 3

3. Jun 8, 2026 Clinical update

   acetylsalicylic acid — Phase 2

4. Jun 8, 2026 Clinical update

   PRX-115 — Phase 2

5. Jun 8, 2026 Clinical update

   Human Glucocerebrosidase (prGCD) — Phase 1

View all clinical trial activity →

• What is Protalix Biotherapeutics?

  Protalix Biotherapeutics is a biotech organization headquartered in HACKENSACK, NJ, USA. It trades on NYSE under ticker PLX. Primary therapeutic focus areas include Fabry Disease, Bioequivalence, Gaucher Disease, Upper Gastrointestinal Mucosal Damage, Cystic Fibrosis. NovaPharmaN

• Is Protalix Biotherapeutics publicly traded?

  Yes. Protalix Biotherapeutics is listed with ticker PLX on NYSE per SEC EDGAR records linked on this profile.

• What drugs does Protalix Biotherapeutics develop or market?

  We link 14 drug profile(s) where Protalix Biotherapeutics is an originator or marketer in FDA or regional approval metadata. See the drug portfolio table on https://novapharmanews.com/companies/protalix-biotherapeutics#company-drugs.

• What are the latest developments for Protalix Biotherapeutics?

  In the last 12 months our linked public records show 21 trial program update(s) and 1 US patent grant(s) tied to this profile.

• What therapeutic areas does Protalix Biotherapeutics focus on?

  Protalix Biotherapeutics focuses on Fabry Disease, Bioequivalence, Gaucher Disease based on our analysis of their pipeline programs and drug development activities.